SI
CRBP icon

Stephens Inc’s Corbus Pharmaceuticals CRBP Stock Holding History

Stephens Inc’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,250
Closed -$260K – 1153
2019
Q2 		$260K Sell
1,250
-1,367
-52% -$293K 0.01% 979
2019
Q1 		$546K Buy
+2,617
New +$577K 0.01% 733

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Stephens Inc's CRBP Position: Q3 2019 in Review

Stephens Inc sold out of Corbus Pharmaceuticals (CRBP) in Q3 2019, closing a stake of 1,250 shares — an estimated $260K sold.

Stephens Inc first reported a position in CRBP in Q1 2019 and held it in 2 quarters. The position peaked at $546K in Q1 2019. 103 funds tracked by Wall St. Rank hold CRBP as of Q3 2019.

  • Stephens Inc reported no remaining Corbus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Stephens Inc sold 1,250 Corbus Pharmaceuticals shares in Q3 2019, an estimated $260K.
  • Stephens Inc first reported a position in Corbus Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Stephens Inc's Corbus Pharmaceuticals position peaked at $546K in Q1 2019.
  • 103 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2019.

Based on Stephens Inc's 13F filing for Q3 2019, filed 18 Oct 2019.